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Abstract
Chemokines, in concert with cytokines and adhesion
molecules, play multiple roles in local and systemic
immune responses. In the kidney, the temporal and spa-
tial expression of chemokines correlates with local renal
damage and accumulation of chemokine receptor-bear-
ing leukocytes. Chemokines play important roles in leu-
kocyte trafficking and blocking chemokines can effective-
ly reduce renal leukocyte recruitment and subsequent
renal damage. However, recent data indicate that block-
ing chemokine or chemokine receptor activity in renal
disease may also exacerbate renal inflammation under
certain conditions. An increasing amount of data indi-
cates additional roles of chemokines in the regulation of
innate and adaptive immune responses, which may ad-
versively affect the outcome of interventional studies.
This review summarizes available in vivo studies on the
blockade of chemokines and chemokine receptors in kid-
ney diseases, with a special focus on the therapeutic
potential of anti-chemokine strategies, including poten-
tial side effects, in renal disease.
Copyright © 2004 S. Karger AG, Basel
Introduction
Generally, immune responses are mediated by im-
mune cells that are activated before they contribute to
immunity. Immune cell activation is mediated and regu-
lated by a variety of factors including lipid mediators,
immunoglobulins, adhesion molecules, and cytokines.
The superfamily of cytokines includes several families of
chemotactic cytokines, i.e. the chemokines, which me-
diate cell activation via transmembrane surface receptors
on target cells. To facilitate immune cell recruitment and
activation, chemokines are released locally by parenchy-
mal cells as well as by infiltrating cells in injured organs.
Chemokines have a prominent role in leukocyte migra-
tion to sites of tissue injury [1–5], but they also have many
other additional functions that contribute to immunity
and tissue homeostasis. These include homeostatic func-
tions in leukocyte development, cell trafficking during
immune surveillance, hematopoiesis, and angiogenesis
[6–10]. In the context or renal inflammation, most studies
and recent reviews have focused on the role of chemo-
kines in the recruitment of immune cells into diseased
kidneys [11–13]. However, unexpected data from studies
with chemokine antagonists and from mice genetically
deficient for chemokines or chemokine receptors have
raised new questions about additional roles of chemo-
kines in the inflammatory process. In this review we pro-
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vide a brief introduction on chemokine biology and then
focus on potentially confounding effects of chemokines in
renal disease which have to be considered for future
research in this field.
The Chemokine Superfamily
Chemokines are a family of low-molecular-weight cy-
tokines first characterized by their ability to induce
directed migration of leukocytes [1–3]. Although chemo-
kines have a relatively low level of sequence identity, their
three-dimensional structure is highly homolog in that they
all have the same monomeric fold. This fold results from a
four-cysteine motif that forms two characteristic disulfide
bridges. Depending on the relative position of the first
two cysteines, chemokines are divided into CC, CXC, C,
and CX3C subfamilies [6]. The systematic nomenclature
describes individual chemokines (ligands L) and their
receptors (R) on the basis of subgroups they belong to
(fig. 1) [6, 14]. Chemokines can be further categorized
into two classes depending on whether they are constitu-
tively produced or are inducible [10, 15]. The first group,
the homeostatic chemokines, are instrumental in basal
leukocyte development and trafficking during immune
surveillance. In contrast, inflammatory chemokines are
induced by proinflammatory stimuli and orchestrate in-
nate and adaptive immune responses, for example by
recruitment of leukocytes to sites of tissue injury and reg-
ulation of T cell, monocyte and dendritic cell differentia-
tion.
Chemokine Receptors
All chemokines signal through G-protein-coupled sev-
en-transmembrane receptors. Chemokine receptors are
named and classified according to their chemokine li-
gand(s), that is C, CC, CXC, and CX3C receptors (fig. 1)
[6, 14]. Each chemokine receptor has a distinct chemo-
kine specificity and a restricted expression on subclasses
of leukocytes (and non-hematopoietic cells). However,
ligand specificities of the receptors can substantially over-
lap within a chemokine class leading to redundancy in the
system. Some receptors bind multiple chemokines, and
others share the same ligands (fig. 1). In general, the
proinflammatory chemokine receptors have more prom-
iscuous ligand-binding specificities, while receptors in-
volved in basal leukocyte development and trafficking
have fewer ligands. Although in vitro binding and activa-
tion studies suggest a high degree of redundancy in the
chemokine system, this might actually be not true in vivo.
Indeed, genetic and an increasing number of functional
studies have largely confirmed that single chemokines
and receptors play non-redundant roles in immune biolo-
gy [15, 16]. The complexity of the system may be further
enhanced by the fact that chemokine receptors can form
heterodimers with new ligand specificities and that some
chemokines or their metabolites can even act as antago-
nists for their receptors [17]. This seemingly confusing
system allows for highly adaptable and dynamic re-
sponses.
Chemokines Regulate Leukocyte Trafficking
Leukocyte extravasation from the blood into the tis-
sues is a highly regulated and selective process, involving
multiple ligand receptor interactions between the circulat-
ing leukocyte and endothelial cells. A multistep paradigm
was developed that describes discrete stages of this inter-
action [18, 19]. Through transient interactions between
selectins and selectin ligands (adressins), a reversible roll-
ing of leukocytes along the endothelial wall is induced [20,
21]. During this rolling phase, leukocytes are brought in
contact with chemokines that are retained on heparan sul-
fate proteoglycans of the endothelial surface following
secretion by activated endothelial cells, activated plate-
lets, and subendothelial parenchymal cells. Chemokine
signaling through specific, leukocyte-expressed G-pro-
tein-coupled receptors activates integrins, resulting in
irreversible firm adhesion of the leukocyte to the endothe-
lial surface, where integrin ligands, the intercellular adhe-
sion molecules of the immunoglobulin superfamily, are
expressed [5, 22, 23]. This arrest is the prerequisite allow-
ing subsequent spreading, diapedesis, and transmigration
of the leukocyte into the inflamed tissue. Thus, chemo-
kine signaling converts the low-affinity, selectin-mediated
leukocyte-endothelial cell interaction into the high-affini-
ty, integrin-mediated interaction that leads to extravasa-
tion of leukocytes. Different chemokines and chemokine
receptors appear involved during the initial leukocyte-
endothelial interaction and the subsequent transendothe-
lial migration [16]. Therefore, expression of a chemokine
in a tissue and the presence of its receptor on a circulating
leukocyte substantially contribute to the selectivity of the
local leukocyte recruitment.
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Fig. 1. Chemokines and chemokine recep-
tors. Abbreviations are: i = inflammatory;
h = homeostatic. The abbreviations of the
common names are as follows: GCP-2 =
granulocyte chemotactic protein-2; IL-8 =
interleukin-8; Gro = growth-regulated onco-
gene; KC = keratinocyte-derived chemokine;
MIP = macrophage inflammatory protein;
CINC = cytokine-induced neutrophil che-
moattractant; ENA78 = epithelial cell-de-
rived neutrophil-activating peptide 78;
NAP-2 = neutrophil-activating peptide-2;
PF4 = platelet factor 4; MIG = monokine
induced by interferon-Á; IP-10 = interferon-
inducible protein-10; I-TAC = interferon-
inducible T-cell · chemoattractant; SDF-1 =
stromal cell-derived factor-1; BCA-1 = B
cell-attracting chemokine-1; BRAK = breast
and kidney-expressed chemokine; SR-PSOX
= scavenger receptor for phosphatidylserine
and oxidized lipoprotein; RANTES = regu-
lated on activation, normal T-cell expressed
and secreted; MCP = monocyte chemoat-
tractant protein; MPIF = myeloid progenitor
inhibitory factor; HCC = hemofiltrate CC
chemokine; TARC = thymus and activation-
regulated chemokine; MDC = macrophage-
derived chemokine; DC-CK1 = dendritic
cell chemokine 1; LARC = liver and activa-
tion-regulated chemokine; ELC = EBI1 li-
gand chemokine; SLC = secondary lymphoid
tissue chemokine; TCA-3 = T-cell activation
protein-3; TECK = thymus-expressed che-
mokine; CTACK = cutaneous T-cell-attract-
ing chemokine; ESkine = embryonic stem
cell-derived chemokine; MEC = mucosae-
associated epithelial chemokine; SCM-1ß =
single cysteine motif-1ß chemokine.
Chemokines Chemokine receptors 
Common
names 
Function
GCP-2    (i)          CXCL6
IL-8  (i)          CXCL8
Gro-α, KC, MIP-2    (i)          CXCL1
Gro-β, CINC-2α (i) CXCL2
Gro-γ, CINC-2β (i)          CXCL3 
ENA78 (i)          CXCL5
NAP-2 (i)          CXCL7
PF4 (i)          CXCL4
MIG (i)          CXCL9
IP-10 (i)          CXCL10
I-TAC (i)          CXCL11
SDF-1 (h) CXCL12
BCA-1 (h) CXCL13
Bolekine, BRAK (i)          CXCL14
Lungkine (h) CXCL15
SR-PSOX (?) CXCL16
MIP-1α (i)          CCL3
RANTES (i)          CCL5
MCP-3 (i)          CCL7
MIP-3, MPIF-1 (i)          CCL23
MCP-1 (i)          CCL2
MCP-2 (i)          CCL8 CCR2
MCP-4 (i)          CCL13
HCC-1, HCC-3 (i)          CCL14
HCC-2 (i)          CCL15
HCC-4 (i)          CCL16
Eotaxin (i)          CCL11
MPIF-2, eotaxin-2 (i)          CCL24 CCR3
MIP-4α, eotaxin-3 (i)          CCL26
TARC (h) CCL17
MDC (h) CCL22
MIP-1β (i)          CCL4 CCR5
DC-CK1 (h?) CCL18 
MIP-3α, LARC (h) CCL20 CCR6
ELC (h) CCL19
SLC (h) CCL21
I-309, TCA-3 (i)          CCL1 CCR8
TECK (h) CCL25 CCR9
CTACK, ESkine (h) CCL27
MEC (h) CCL28
Lymphotactin (i)          XCL1
SCM-1β (i) XCL2
Fractalkine (i)          CX3CL1 CX3CR1
CXCR1
CXCR2
CXCR3
CXCR4
CXCR5
CXCR6
CCR7
CCR10
CCR11
XCR1
CCR1
CCR4
Systematic
names
C
X
3C
-
C
C
-
C
C
-C
h
em
o
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C
X
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Chemokines Have Multiple Other Functions in
Local and Systemic Immune Responses
In addition to their role in leukocyte trafficking, che-
mokines play important roles in innate and adaptive
immune responses. This includes leukocyte activation,
dendritic cell function, lymphocyte function during im-
mune surveillance and response, lymphocyte maturation
and differentiation, and hematopoiesis and angiogenesis
[2, 3, 6–10].
Chemokines stimulate leukocyte degranulation or re-
lease of inflammatory mediators. For example, CXCL8/
interleukin (IL)-8 stimulates neutrophil degranulation,
and CCL2/MCP-1 is a potent stimulator of histamine
release by basophils [3]. Moreover, chemokines, like
CXCL8/IL-8 and CCL5/RANTES, induce respiratory
burst in granulocytes and macrophages leading to the
local production of reactive oxygen species [3]. CCL5/
RANTES has also been shown to costimulate T-lympho-
cyte activation [24].
Cell migration and positioning is central at diverse
phases of the adaptive immune response, hence chemo-
kines and their receptors are critically involved in many
aspects of adaptive immunity. A number of studies have
shown that the ability of dendritic cells to migrate into
inflamed tissue and then to the draining lymph node for
antigen presentation is based on differential chemokine
receptor expression on the dendritic cell [3, 6]. Immature
dendritic cells express receptors for inflammatory chemo-
kines such as CCR1, CCR2, CCR5, and CCR6, which are
then downregulated as the cells mature. Mature dendritic
cells upregulate expression of lymphoid-homing chemo-
kine receptors such as CCR7, guiding them to lymph
nodes, where the CCR7 ligands CCL19/ELC and CCL21/
SLC are expressed [3, 6].
Within lymphoid tissue, the complex cellular interac-
tion between naive T and dendritic cells or between T and
B cells are also controlled by chemokines [3, 6, 25]. Naive
T cells express CCR7, that facilitates their location to
lymphoid tissue during immune surveillance. In contrast,
subsets of effector and memory T cells express proinflam-
matory chemokine receptors like CCR2, CCR3, CCR5,
CCR6, CCR8 or CXCR5, that facilitate recruitment into
inflamed non-lymphoid tissue during the effector phase
or positioning within lymph node follicles for generation
of antibody producing B-cells. Mature B cells uniformly
express CXCR5 and migrate into follicles in response to
the CXCR5 ligand CXCL13/BCA-1 [3, 6, 25].
Chemokines also regulate effector T-cell differentia-
tion [7]. For example, CCL2/MCP-1-deficient mice have
diminished Th2 responses and their T cells do not secrete
IL-4, IL-5 and IL-10, although IFN-Á and IL-2 production
are unaffected. These mice cannot achieve the immuno-
globulin E subclass switch that is characteristic for Th2
responses and are more resistant to Th2-associated dis-
ease [26]. Conversely, a positive regulatory effect on Th1
cell differentiation has been suggested for CCR5 and
its ligands CCL3/MIP-1·, CCL4/MIP-1ß, and CCL5/
RANTES by inducing expression of IL-12 by antigen-pre-
senting cells and by directly polarizing Th cells to secrete
IFN-Á [7]. Moreover, a number of chemokine receptor
associations with the Th1 and Th2 phenotype have been
reported. While CCR1, CCR5 and CXCR3 are expressed
on Th1 cells, CCR3, CCR4, and CCR8 have been associ-
ated with the Th2 phenotype [6, 7]. This allows a differ-
ential recruitment of Th1 or Th2 cells to sites of inflam-
mation, where chemokines are often differentially in-
duced in response to different pathogens and stimuli.
Expression of Chemokines by Activated Renal
Cells
All types of intrinsic renal cells including endothelial
cells, podocytes, mesangial cells, tubular epithelial cells,
and interstitial fibroblasts can produce inflammatory che-
mokines upon stimulation [reviewed in 12]. In vitro stud-
ies demonstrated that chemokine production of all types
of renal cells is induced by proinflammatory stimuli such
as reactive oxygen species, cytokines (TNF-·, IL-1ß,
IFN-Á), vasoactive substances like angiotensin II, and
pathogen-associated molecules such as lipopolysaccha-
ride [12]. Subsequently, infiltrating leukocytes are a major
source of local chemokine production in the kidney, for
example MIP-1· seems to be exclusively produced by
infiltrating macrophages [27–30]. A positive amplifica-
tion loop is formed, as chemokines secreted by infiltrating
leukocytes promote further local leukocyte recruitment
and activation.
Association of Chemokine Expression with
Renal Injury
Several studies have localized the expression of chemo-
kines in animal models of glomerular and tubulointersti-
tial disease by in situ hybridization and immunohisto-
chemistry [reviewed in 13]. For example, expression of
CCL2/MCP-1 and CCL5/RANTES localized to intrinsic
renal cells and infiltrating leukocytes confirming the in
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vitro data mentioned earlier. Expression of various in-
flammatory chemokines is generally restricted to the
injured compartment of the kidney [12, 13]. In acute
immune complex glomerulonephritis, chemokines are ex-
clusively produced within glomeruli [27, 31], whereas in
interstitial nephritis induced by unilateral ureteral ob-
struction, chemokine expression is confined to the inter-
stitial compartment [28]. When progression of a glomeru-
lar disease leads to secondary tubulointerstitial damage,
chemokines are produced in both diseased compart-
ments, for example during murine lupus nephritis [32,
33]. Moreover, the spatial expression of chemokines cor-
relates with local accumulation of chemokine receptor-
positive leukocytes at sites of renal damage [27, 28, 33].
Chemokines are involved both in the initiation and
progression of renal disease [reviewed previously in detail
in 13]. On the one hand, termination of the chemokine
signal is critical for the resolution of the inflammatory
process [27]. On the other hand, when local chemokine
expression is augmented and prolonged by additional
proinflammatory stimuli that may be independent of the
initial injury, the ongoing recruitment of inflammatory
cells leads to accelerated progression of a preexisting renal
disease towards severe renal damage with loss of organ
function [34, 35]. Thus, even if the initial injury to the
kidney subsides, chemokine-mediated leukocyte recruit-
ment can be maintained or, in the case of a chronic dis-
ease process, exacerbated by other mechanisms such as
infection, activation of the renin-angiotensin system, hyp-
oxia, and proteinuria [34, 35].
Taken together, these observations support the concept
that chemokines, locally produced by intrinsic renal cells
and infiltrating inflammatory cells, are involved in me-
diating local immunity such as renal leukocyte recruit-
ment and inflammation. Importantly, the relevance of the
animal data for human disease has been confirmed by
various human biopsy studies that demonstrated similar
expression patterns of chemokines and chemokine recep-
tors in relation to renal leukocyte infiltration and tissue
damage [36–43].
Chemokines in Glomerulonephritis
The functional roles of chemokines in the pathogenesis
of acute glomerulonephritis have been demonstrated in
various animal models by blocking chemokine activity
with neutralizing antibodies, chemokine receptor antago-
nists, and targeted disruption of chemokine and chemo-
kine receptor genes [12, 13]. However, some of these stud-
ies yielded conflicting results illustrating the multifaceted
roles of chemokines in leukocyte trafficking and immune
responses.
Chemokines Mediate Glomerular Leukocyte
Recruitment
Several studies utilized the nephrotoxic serum nephri-
tis model in the rat and mouse. In the rat, neutralizing
antibodies to CXC chemokines, including CXCL1/MIP-2
and CINC, reduced glomerular neutrophil infiltration
and proteinuria during the acute phase of the model [29,
44, 45]. Blockade of the CXC chemokine receptor
CXCR2, which binds multiple CXC chemokines includ-
ing CXCL1/MIP-2 and CINC, with the peptide analog
Gro-·8–73, demonstrated a role of CXCR2 in mediating
glomerular monocyte recruitment in the rat nephrotoxic
nephritis model [46]. Inhibition of multiple CC and CXC
chemokine receptors by vMIP-II, a viral broad chemo-
kine antagonist encoded by human herpesvirus 8, also
decreased proteinuria and glomerular infiltration of mac-
rophages and CD8+ T cells in rats [47]. Blocking the
CX3CL1/fractalkine receptor CX3CR1 with a neutraliz-
ing antibody improved renal function and prevented
crescentic glomerulonephritis in rat nephrotoxic nephritis
[48]. In the same model, antibody blockade of the CC che-
mokine CCL22/macrophage-derived chemokine reduced
glomerular macrophage influx, prevented crescent forma-
tion, and reversed renal functional impairment [31].
Targeting CCL2/MCP-1 and Its Receptor CCR2
Yields Conflicting Results in Antagonist Studies and
Knockout Mice
Neutralizing antibodies to the CC chemokine CCL2/
MCP-1, a major monocyte/macrophage chemoattractant,
blocked glomerular infiltration of macrophages in the rat
anti-Thy-1.1 nephritis model [49]. Treatment with anti-
CCL2/MCP-1 antibodies also reduced glomerular macro-
phage influx and proteinuria in rat nephrotoxic serum
nephritis [50–52] and abrogated glomerular and intersti-
tial leukocyte infiltration, proteinuria, crescent formation
and interstitial collagen deposition in murine nephrotoxic
nephritis [53]. Consistently, a preliminary report demon-
strated that blockade of the CCL2/MCP-1 receptor CCR2
with a series of novel antagonists ameliorated disease,
including glomerular injury, in the rat model [54]. Tubu-
lointerstitial damage but not glomerular histopathology
was reduced in rats with nephrotoxic serum nephritis
when CCL2/MCP-1 expression was selectively blocked in
tubular epithelial cells by an antisense approach [55].
These studies clearly support a functional role of CCL2/
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MCP-1 signaling in experimental glomerulonephritis.
Surprisingly, however, contradictory results have been
obtained in mice with targeted gene deletion of CCL2/
MCP-1 and CCR2. In CCL2/MCP-1-deficient mice with
nephrotoxic serum nephritis, glomerular injury and pro-
teinuria were comparable to wild-type mice, and only the
tubulointerstitial injury was reduced [56]. Moreover, in
mice lacking CCR2, the proteinuria and glomerular pa-
thology of nephrotoxic serum nephritis was worse, despite
reduced glomerular macrophage infiltration [57]. Al-
though compensatory chemokine and chemokine recep-
tor systems may develop in genetically deficient mice, the
discrepant results have important implications. In view of
their roles in adaptive immunity, targeting CCL2/MCP-1
and CCR2 in acute glomerulonephritis may not simply
interfere with renal leukocyte recruitment and activation,
but may fundamentally alter the systemic immune re-
sponse that subsequently causes the glomerular injury, for
example by augmenting Th1 effector mechanisms. As dis-
cussed earlier, CCL2/MCP-1-deficient mice have dimin-
ished cellular and humoral Th2 responses. Moreover,
CCL2/CCR2 signaling may be important to activate
CCR2-positive regulatory T cells, which are essential to
downregulate adaptive immune responses (see below).
Blockade of the CCL5/RANTES Receptors Can Have
Beneficial and Adverse Effects in Glomerulonephritis
Beneficial effects of two CCL5/RANTES analogs, ami-
no-oxypentane (AOP)-RANTES and Met-RANTES,
which block binding of human CCL5/RANTES to its
receptors CCR1, CCR3, and CCR5, have been demon-
strated in rodent studies. AOP-RANTES inhibited glo-
merular macrophage infiltration and collagen IV deposi-
tion in the anti-Thy-1.1 model [58]. Lloyd et al. [53]
showed that Met-RANTES reduced glomerular and inter-
stitial leukocyte infiltration and proteinuria in murine
nephrotoxic serum nephritis, although glomerular cres-
cent formation and renal collagen deposition was not
effected. However, the antagonists Met-RANTES and
AOP-RANTES both aggravated glomerular damage and
proteinuria in a murine model of acute immune-complex
glomerulonephritis, despite reduction of glomerular mac-
rophage infiltration [59]. This was associated with an
enhanced proinflammatory state of the macrophages
present in the glomerulus, indicated by increased induci-
ble NO synthetase expression and reduced uptake of
apoptotic cells [59]. The effect of CCL5/RANTES antago-
nists on apoptotic cell uptake is of special interest and is
another indication of yet poorly understood roles of che-
mokines. Thus, despite effectively blocking glomeru-
lar leukocyte recruitment, Met-RANTES and AOP-
RANTES altered the phenotype of the resident macro-
phages, possibly due to agonistic effects on the CCL5/
RANTES receptors, which have been described for these
CCL5/RANTES analogs [60]. As mentioned, the CCL5/
RANTES antagonist Met-RANTES reduced leukocyte in-
filtration and proteinuria in mice with nephrotoxic ne-
phritis [53]. However, disease was not ameliorated in
mice deficient for the CCL5/RANTES receptor CCR5
[61], although this may be explained by compensatory uti-
lization of other CCL5/RANTES receptors. Importantly,
CCR1-deficient mice developed more severe glomerular
pathology, greater proteinuria and an increased renal
infiltration of macrophages and T cells during nephro-
toxic nephritis [62]. Interestingly, enhanced Th1 re-
sponses were noted in these mice, again suggesting an
altered systemic immune response in the effector phase as
a potential mechanism of exacerbation [62].
Taken together, these data add to the growing evidence
that chemokines do not only promote renal leukocyte
recruitment and activation, but also modulate the sys-
temic immune response and the phenotype of infiltrating
cells during renal inflammation. Consequently, blockade
of specific chemokines or chemokine receptors may po-
tentially induce adverse reactions rather than reduce renal
injury, especially in primarily immune-mediated renal
disease. Importantly, with systemic immune responses
and potential compensatory pathways differentially af-
fected, functional studies in knockout mice and transient
blockade of chemokines with antibodies or antagonists
can yield different and in part conflicting results. This will
be greatly influenced by the type of disease model investi-
gated, and will be less likely in models that involve innate
effector mechanisms (like the heterologous phase of the
nephrotoxic serum nephritis), as in those requiring an
adaptive immune response (like the nephrotoxic nephritis
in its autologous phase).
Chemokines in Acute Renal Failure
Although most functional studies used experimental
models of immune-mediated renal disease, a role of che-
mokines and chemokine receptors in the pathogenesis of
acute renal failure has been demonstrated [63]. In renal
ischemia-reperfusion injury, neutralizing antibodies to
the CXC chemokines CXCL1/Gro-· and MIP-2 blocked
interstitial neutrophil infiltration, reduced renal damage
and improved survival of treated mice [64]. Furuichi et al.
[65] showed that CCR2-deficient mice subjected to renal
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ischemia-reperfusion injury had reduced interstitial mac-
rophage infiltrates and less tubular necrosis than wild-
type mice. Moreover, ischemia-reperfusion injury and
macrophage infiltration decreased when mice were trans-
fected with the gene construct 7ND that encodes a trun-
cated CCL2/MCP-1 protein and blocks activation of
CCR2 by all of its endogenous ligands including CCL2/
MCP-1, CCL7/MCP-3, CCL8/MCP-2, and CCL13/
MCP-4 [66]. These studies indicate that chemokines play
a functional role in acute non-immune-mediated renal
injury. Blockade of the CXC chemokine-dependent inter-
stitial neutrophil influx or CCL2/CCR2-mediated macro-
phage infiltration may be a valuable therapeutic strategy
in acute renal failure. However, there is growing evidence
that lymphocytes also play important roles in primarily
non-immune-mediated renal disease such as ischemia-
reperfusion injury [67, 68]. Thus, chemokine blockade in
this setting may have unforeseen effects by modulating
components of the adaptive immune response. This must
be carefully considered before therapeutic strategies are
applied in humans.
Chemokines in Renal Transplant Rejection
Because of the predominant cell-mediated immune
response, transplantation would appear as an ideal target
for chemokine blockade in a therapeutic modality. In a
rabbit model of acute renal allograft rejection, renal func-
tion and tubulointerstitial damage improved when the
CC chemokine receptor CCR1 was blocked with the small
peptide antagonist BX471 [69]. In rat models of acute
renal allograft rejection, treatment with the CCL5/
RANTES antagonist Met-RANTES significantly reduced
vascular and tubular damage, and suppressed mononu-
clear cell infiltration associated with acute rejection [70].
These results were expanded on in a recent study where
treatment with Met-RANTES for 7 days after renal trans-
plantation in rats improved chronic transplant function
with reduced proteinuria, glomerulosclerosis, and inter-
stitial fibrosis after 28 weeks [71]. As leukocytes express-
ing the CCL5/RANTES receptor CCR5 are frequently
found in interstitial cell infiltrates of human renal trans-
plants [41, 72], these data may also be relevant to human
transplant nephropathy. The strongest support for this
hypothesis comes from a multicenter case-control study
in human renal transplant recipients [73]. In humans, a
32-bp deletion (¢32) in the CCR5 gene generates a non-
functional receptor, with a homozygous prevalence of
about 1% in the Caucasian population. These ¢32 homo-
zygotes show no apparent phenotype. When the influence
of the ¢32 mutation of CCR5 was analyzed in over 570
renal transplant recipients, long-term graft survival was
significantly better in the homozygous ¢32 CCR5 group
compared to either the heterozygote or wild-type trans-
plant recipients, suggesting a pathophysiological role of
CCR5 in transplant nephropathy [73]. Of note, the num-
ber of acute rejections was not influenced by the ¢32
mutation of CCR5 in this study. As chronic allograft
nephropathy emerges as a major problem in renal trans-
plantation, the potential role of CCR5-positive leukocytes
in this process may be of special interest. Possibly CCR5-
positive cells in the transplant may play a role in the pro-
cess of chronic transplant nephropathy. A detailed analy-
sis of various chemokine receptor polymorphisms in hu-
man renal transplant recipients revealed another muta-
tion of CCR5 (homozygous for the 59029-A allele) as well
as a CCR2 deletion (CCR2-64I allele) which significantly
reduced the frequency of acute rejection episodes [74].
However, a recent study by other investigators could not
find a protective effect of the CCR2-64I allele in acute or
chronic rejection [75]. One problem with such association
studies may lie in the relative small numbers of cases
examined, which may lack adequate statistical power to
come to valid conclusions. Interestingly, Kruger et al. [75]
did demonstrate a higher risk for premature kidney graft
failure in transplant recipients homozygous for the CCL2/
MCP-1 mutation 2518G. Peripheral blood mononuclear
cells isolated from these patients were characterized by a
2.5-fold higher CCL2/MCP-1 secretion, which may aug-
ment CCL2/MCP-1-dependent leukocyte recruitment
and activation into the allograft.
These data suggest that chemokine-mediated leuko-
cyte influx and activation play both roles in acute rejec-
tion and in chronic transplant nephropathy. Particularly
CCR5 may be a promising target for therapeutic interven-
tion to prevent progression of chronic transplant loss,
especially as the absence of functional CCR5 in humans is
not associated with any deleterious phenotype.
Chemokines in the Progression of Renal
Disease
Several recent studies, including work from our own
laboratory, evaluated the role of chemokines in the pro-
gression of renal disease. As the glomerular and intersti-
tial infiltrate in chronic nephropathies mainly consists of
macrophages and T cells, these studies focused on chemo-
kines predominantly targeting mononuclear cells, that is
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CC chemokines, and their receptors. Progression of var-
ious chronic nephropathies to end-stage renal disease cor-
relates best with progressive tubulointerstitial injury and
renal fibrosis [13, 76]. The accumulation of interstitial
leukocytes as a major source of proinflammatory and pro-
fibrotic cytokines is critical for this process, characterized
by tubular damage, interstitial fibroblast accumulation
and matrix deposition. Blocking the chemokine-mediated
recruitment and activation of interstitial leukocytes may
therefore be a potential therapeutic strategy for progres-
sive renal disease independent of the primary lesion.
Targeting CCR1 Ameliorates Interstitial
Inflammation and Fibrosis
We have recently shown that blockade of the CC che-
mokine receptor CCR1 with the small molecule antago-
nist BX471 substantially reduced interstitial leukocyte
infiltration, interstitial fibroblast accumulation, and in-
terstitial matrix deposition in murine obstructive ne-
phropathy as a model of progressive interstitial inflamma-
tion and fibrosis [77]. Importantly, blockade of CCR1 at a
later time point, when significant tubulointerstitial injury
was already present, was effective in reducing the disease
progression [77]. A role for CCR1 in mediating leukocyte
recruitment and interstitial fibrosis was subsequently con-
firmed by similar studies with CCR1-deficient mice using
the same model [78]. Of note, the CC chemokine receptor
CCR5 appears not to be instrumental in these processes,
as interstitial leukocyte infiltration and markers of renal
fibrosis were not altered in CCR5-deficient mice [78].
These studies identified CCR1 as a promising target for
reducing interstitial inflammation and fibrosis as major
determinants in the progression of chronic nephropathies.
Similarly, blockade of CCR1-dependent leukocyte infil-
tration has been shown to decrease tissue fibrosis in other
organs than kidney. Tokuda et al. [79] have developed a
polyclonal antibody with blocking activity against CCR1.
When given in the mouse model of bleomycin-induced
pulmonary fibrosis, a marked reduction of leukocyte infil-
trates and interstitial fibrosis was found, which was asso-
ciated with increased survival of treated mice.
However, as discussed earlier, chemokines are not only
involved in local leukocyte recruitment and activation,
but are also regulators of systemic immune responses.
Thus, data obtained in the obstructive nephropathy mod-
el may not apply to renal disease caused by immune-
mediated mechanisms. We therefore studied the effects of
therapeutic CCR1 blockade in the progressive renal inju-
ry of lupus-like nephritis in MRL/MPJ FASlpr/lpr (MRL/
lpr) mice. In these mice a progressive immune-complex
glomerulonephritis with tubulointerstitial disease devel-
ops, resulting in end-stage renal failure as in human lupus
nephritis. CCR1 and its chemokine ligands are increas-
ingly expressed in kidneys of MRL/lpr mice [33]. When
BX471 treatment to block CCR1 was given late during
the course of disease (at 20–24 weeks of age), blood urea
nitrogen levels improved, and the extent of interstitial leu-
kocyte infiltration and fibrosis was reduced [80]. Cell
transfer studies with labeled macrophages and T cells that
were pretreated with either vehicle or BX471 confirmed
the CCR1-dependent recruitment of these cells to the
renal interstitium of MRL/lpr mice. In view of the aggra-
vated disease in CCR1-deficient mice with nephrotoxic
serum nephritis [62], it is particularly important that
blockade of CCR1 in MRL/lpr mice did not affect pro-
teinuria, glomerular injury, and serum levels of DNA
autoantibodies, suggesting that CCR1 blockade with
BX471 did not alter systemic autoimmunity in these
mice. However, these data also indicate that targeting
CCR1 in chronic glomerulonephritidis may not alter the
glomerular disease process, in spite of having beneficial
effects on the progressive tubulointerstitial inflammation
and fibrosis.
Sustained proteinuria is a major prognostic factor for
the progression of renal disease [13]. Albumin exposure
and tubular intraluminal complement can induce chemo-
kine expression by renal tubular epithelial cells, suggest-
ing that proteinuria may significantly contribute to tubu-
lointerstitial inflammation [81, 82]. We therefore exam-
ined the effects of CCR1 blockade with BX471 in murine
adriamycin nephropathy, a model of focal segmental glo-
merulosclerosis with nephrotic syndrome and progressive
interstitial fibrosis. BX471 treatment was started at day
14 when proteinuria had already developed. Again,
BX471 significantly reduced the number of infiltrating
macrophages and T cells in the interstitium, and markers
of renal fibrosis, including interstitial fibroblast accumu-
lation and volume expansion [83]. In contrast, the extent
of proteinuria and glomerulosclerosis was not affected by
BX471 treatment. These findings together with the data
obtained in the MRL/lpr mice demonstrate that the bene-
ficial effects of therapeutic CCR1 blockade in progressive
renal injury are confined to the interstitial compartment,
but can occur despite persisting proteinuria.
Blockade of CCL2/MCP-1 and CCR2 May Have
Beneficial, but Also Adverse Effects in Progressive
Renal Injury
In addition to CCR1, roles of CCL2/MCP-1 and its
receptor CCR2 have been identified in animal models of
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progressive nephropathies. Shimizu et al. [84] recently
reported that local transfection of a gene construct encod-
ing the CCL2/MCP-1 antagonistic protein 7ND attenuat-
ed interstitial macrophage infiltration and tubulointersti-
tial injury in rats with protein-overload proteinuria. A
preliminary report also noted beneficial effects of gene-
transferred 7ND in murine obstructive nephropathy,
where interstitial macrophages and markers of renal fi-
brosis were reduced [85]. Similar results were obtained
using mice genetically deficient for the CCL2/MCP-2
receptor CCR2 and by blockade of CCR2 with the inhibi-
tor propagermanium [85].
When CCL2/MCP-1-deficient mice were crossbred
with lupus-prone MRL/lpr-mice, lack of CCL2/MCP-1
reduced proteinuria, glomerular and tubulointerstitial pa-
thology, without affects on serum immunoglobulin iso-
types or renal immune and complement deposits [32].
Glomerular and interstitial infiltration of macrophages
was diminished, and decreased interstitial T-cell infil-
trates were noted. Recently, similar results were obtained
in MRL/lpr mice treated with a CCL2/MCP-1 antagonist
[86]. Although beneficial effects on interstitial disease
may be indirect as a consequence of less glomerular dam-
age and proteinuria causing less tubulointerstitial injury,
the data clearly suggest a pathophysiologic role of CCL2/
MCP-1-dependent leukocyte infiltrates in murine lupus
nephritis. However, these findings differ from earlier data
obtained in the nephrotoxic serum nephritis model,
where tubulointerstitial, but not glomerular disease was
diminished in CCL2/MCP-1-deficient mice with acute
glomerulonephritis [56]. Importantly, a recent study re-
ported that lupus nephritis in MRL/lpr mice was aggra-
vated when CCR2 was blocked with a neutralizing anti-
body. Although proteinuria was unchanged, these mice
showed 2- to 3-fold higher numbers of infiltrating renal
macrophages and T cells, and more severe interstitial
fibrosis [87]. Plasma cytokine levels for IFN-Á and IL-6
were significantly increased. Thus, CCR2 antagonism ag-
gravated both systemic and local inflammatory responses.
Preliminary data suggested that blockade of CCR2-posi-
tive regulatory T cells was responsible for this exacerba-
tion [87]. A dual role of CCR2 in chronic inflammatory
disease has been recently shown in a model of collagen-
induced arthritis [88]. CCR2 blockade in the initiation
phase of the disease improved clinical signs of arthritis
and histological scores including leukocyte infiltration
and joint destruction. CCR2 antagonism was associated
with a decreased cellular and humoral immune response
against collagen, as also noted in MCP-1-deficient mice,
possibly due to impaired migration of antigen-presenting
cells or direct effects on effector T cells. However, late
onset blockade during the progression phase markedly
aggravated arthritis and increased the humoral immunity
against collagen. Again, blockade of CCR2-positive regu-
latory T cells, which apparently have important roles in
down-modulating chronic inflammatory responses, was
implicated in this finding [88].
Taken together, available data indicate that CCR1 and
CCL2/CCR2 signaling mediate leukocyte recruitment
and renal injury during the progression of chronic ne-
phropathies. Interestingly, it appears that the role of
CCR1 is limited to the interstitial compartment, whereas
the CCL2/CCR2 system may mediate both glomerular
and interstitial leukocyte influx and damage. Importantly,
the blockade of CCR2 in more advanced disease may tar-
get leukocyte subpopulations with anti-inflammatory
properties. This may exacerbate chronic nephropathies
instead of improving their outcome. This novel role of
chemokine receptors in directing regulatory T cells opens
up an entirely new field of investigation, that is the role of
chemokines in regulatory T-cell responses and thus in the
modulation of local immune tolerance.
Conclusions for Targeting Chemokines in Renal
Disease
From the above, several new paradigms may evolve for
future research in the field of targeting chemokines in
chronic inflammation including immune-mediated renal
disease:
1. Leukocyte recruitment is only one of many functions
of proinflammatory chemokines. For example, immune
cell activation is another important function of proin-
flammatory chemokines such as CCL5/RANTES. In fact,
under certain conditions, chemokine antagonists can ag-
gravate glomerulonephritis in spite of efficiently blocking
glomerular leukocyte recruitment. This could be me-
diated by acting as a partial agonist on resident glomeru-
lar macrophages [59]. Furthermore, chemokines such as
CCL5/RANTES may also be involved in the uptake of
apoptotic cells and as such in preventing excessive inflam-
mation. This may also be one problem of the use of CCL5/
RANTES antagonists in acute glomerulonephritis, where
apoptosis plays an important role in the resolution of the
disease. Additional roles of chemokines and chemokine
receptors such as in dendritic cell maturation and in regu-
latory T-cell trafficking have to be considered as well.
Finally, there are independent species differences in the
role of chemokines and chemokine receptors. For exam-
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Fig. 2. Potential sites for chemokine antagonists to block renal leukocyte recruitment and activation. Chemokine
antagonists may block multiple phases of this process, including chemokine-mediated integrin activation and subse-
quent firm arrest of the leukocyte to the endothelium (1), transmigration and diapedesis into the interstitium (2),
migration along a chemokine gradient and localization within the inflamed microenvironment (3), and chemokine-
mediated activation of leukocyte effector functions (4). Moreover, chemokine antagonists may alter migration prop-
erties of antigen-presenting cells towards inflamed tissue and secondary lymphoid organs (5), and the generation of
leukocyte effector cell populations within lymphoid organs (6), resulting in an altered immune response to the initial
tissue injury.
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ple, CCR2 is present on regulatory T cells in mice, but not
in humans.
2. Chemokine antagonists can have different outcomes
in different renal disease models, as shown for Met-
RANTES which aggravated apoferritin-induced glomeru-
lonephritis in mice [59], but improved acute and chronic
renal allograft rejection in rats [70, 71]. Therefore, each
chemokine antagonist must be carefully evaluated in ap-
propriate disease models before being applied in the cor-
responding clinical settings.
3. Results with knockout mice can only be used in a
limited manner to assess the therapeutic potential of che-
mokine blockade in disease models that involve adaptive
immune responses. The evolution of adaptive immunity
occurs in different stages that all involve chemokine sig-
naling, for example migration of antigen-presenting cells,
T-cell differentiation, and effector cell migration into the
kidney [6–8]. As it has been shown that blocking certain
chemokines or chemokine receptors in different stages of
this process can result in opposite outcomes of disease
[87, 88], knockout mice cannot predict the effect of che-
mokine blockade in later stages of disease in such models.
A conditional gene targeting approach that allows dele-
tion of gene function at a later time point of the disease
course may help to circumvent this problem.
Nonetheless, chemokine antagonists may be the most
promising approach to assess the therapeutic potential of
chemokine or chemokine receptor blockade. However,
the specificity of the antagonist for the respective chemo-
kine or chemokine receptor has to be carefully docu-
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mented for the species studied. This includes data on neu-
tralization of biological activity of the respective chemo-
kine or chemokine receptor as well as data that show that
neutralization of other chemokines or chemokine recep-
tors of the same class does not occur. In interventional
studies one has to make sure that the antagonist used does
not interfere with the basic mechanisms of induction of
the experimental disease. As the goal should be one of
therapeutic intervention, the antagonists should be evalu-
ated once the disease is established. Only the latter pro-
vides information about the therapeutic use of the antago-
nists in progressive diseases, as chronic diseases such as
renal failure are usually diagnosed and started on treat-
ment in the progressive phase.
In spite of all the reservations, chemokine and chemo-
kine receptor antagonists may prove to be of considerable
therapeutic value, particularly in renal diseases with
chronic progression, where infiltrating leukocytes, such as
T cells, macrophages and dendritic cells play a major role.
Different phases of the cascade of inflammatory cell
recruitment and activation may be influenced by such
antagonists resulting in a reduction of inflammatory effec-
tor cells in the kidney (fig. 2). The generation of small,
orally active inhibitors may allow the evaluation of this
hypothesis in the next decade.
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